Literature DB >> 10227971

Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression.

E M Bennett1, J R Bennink, J W Yewdell, F M Brodsky.   

Abstract

Viral strategies for immune evasion include inhibition of various steps in the class I MHC assembly pathway. Here, we demonstrate that adenovirus produces one gene product with a dual function in this regard. It is well established that adenovirus E19 binds class I molecules and retains them in the endoplasmic reticulum (ER). However, E19 also delays the expression of class I alleles to which it cannot tightly bind. Here, we show that E19 binds TAP and acts as a tapasin inhibitor, preventing class I/TAP association. DeltaE19, an E19 mutant lacking the ER-retention signal, delays maturation of class I molecules, indicating that E19's inhibition of class I/TAP interaction is sufficient to delay class I expression. These data identify tapasin inhibition as a novel mechanism of viral immune evasion and suggest that, through this secondary mechanism, adenovirus can affect Ag presentation by MHC alleles that it can only weakly affect by direct retention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10227971

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein.

Authors:  J M Johnson; C Nicot; J Fullen; V Ciminale; L Casareto; J C Mulloy; S Jacobson; G Franchini
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 2.  Current research on respiratory viral infections: Third International Symposium.

Authors:  A C Schmidt; R B Couch; G J Galasso; F G Hayden; J Mills; B R Murphy; R M Chanock
Journal:  Antiviral Res       Date:  2001-06       Impact factor: 5.970

Review 3.  In vivo immunogenetics: from MIC to RAET1 loci.

Authors:  Mirjana Radosavljevic; Seiamak Bahram
Journal:  Immunogenetics       Date:  2003-03-20       Impact factor: 2.846

Review 4.  The MHC class I antigen presentation pathway: strategies for viral immune evasion.

Authors:  Eric W Hewitt
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

5.  Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.

Authors:  Juergen Bukur; Felix Herrmann; Diana Handke; Christian Recktenwald; Barbara Seliger
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

6.  The endoplasmic reticulum lumenal domain of the adenovirus type 2 E3-19K protein binds to peptide-filled and peptide-deficient HLA-A*1101 molecules.

Authors:  Hong Liu; Walter F Stafford; Marlene Bouvier
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

7.  Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing.

Authors:  Danijela Koppers-Lalic; Eric A J Reits; Maaike E Ressing; Andrea D Lipinska; Rupert Abele; Joachim Koch; Marisa Marcondes Rezende; Pieter Admiraal; Daphne van Leeuwen; Krystyna Bienkowska-Szewczyk; Thomas C Mettenleiter; Frans A M Rijsewijk; Robert Tampé; Jacques Neefjes; Emmanuel J H J Wiertz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-25       Impact factor: 11.205

Review 8.  Viral evasion of the MHC class I antigen-processing machinery.

Authors:  Sandra Loch; Robert Tampé
Journal:  Pflugers Arch       Date:  2005-08-06       Impact factor: 3.657

9.  Pulmonary immunity to viral infection: adenovirus infection of lung dendritic cells renders T cells nonresponsive to interleukin-2.

Authors:  Allison T Thiele; Tina L Sumpter; Joanna A Walker; Qi Xu; Cheong-Hee Chang; Robert L Bacallao; Rajesh Kher; David S Wilkes
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 10.  Pathogen evasion strategies for the major histocompatibility complex class I assembly pathway.

Authors:  Antony N Antoniou; Simon J Powis
Journal:  Immunology       Date:  2008-02-18       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.